{
    "symbol": "LLY",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-01 16:08:02",
    "content": "  For pipeline milestones, we shared several important updates since our Q2 earnings call, including FDA Fast Track designation for tirzepatide for adults with obesity, with completion of a rolling submission expected by mid-2023; EU and Japan approval for Mounjaro for the treatment of adults with type 2 diabetes; U.S. and EU submission of lebrikizumab for moderate to severe atopic dermatitis; and FDA accelerated approval for Retevmo in RET fusion-positive advanced or metastatic solid tumors regardless of tumor type and traditional approval in adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer."
}